MedPath

evetiracetam tablet 1000mg (LEVEBEL 1000mg, Cobel Darou) In- Vivo Bioequivalence study in Iranian healthy volunteers

Not Applicable
Recruiting
Conditions
in this study the bioequivalence of test and brand of levetiracetam will evaluated..
Registration Number
IRCT20200105046010N1
Lead Sponsor
Cobel Darou Pharmaceutical Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
24
Inclusion Criteria

General health (liver & heart & kidney )
Body mass index (18-25)
Informed consent
Age (18-60 )

Exclusion Criteria

Smoking
A history of cardiovascular disease
A history of Liver & Kidney disease
Pregnancy
Alcohol & Drug addiction
Hypersensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Drug analysis in plasma or whole blood. Timepoint: After blood sampling. Method of measurement: HPLC, LC-MS/MS or UPLC-MS/MS.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath